PERPRISE: A prospective non‐interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic–clonic seizures: First interim analysis

Documents similaires

• Effectiveness of perampanel as the only adjunctive anti‐seizure medication in adults: Final results from the observational PERPRISE study in Germany
  par: Bernhard J. Steinhoff, et autres
  Publié: (2025)
• Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions
  par: Stefano Meletti, et autres
  Publié: (2025)
• Effectiveness and safety of implantable vagus nerve stimulation in people with primary generalized tonic–clonic seizures
  par: Katherine Eggleston, et autres
  Publié: (2026)
• Prospective study of epilepsy with generalized tonic–clonic seizures alone: Clinical features, response to treatment, and likelihood of medication withdrawal
  par: Fatima Jaafar, et autres
  Publié: (2024)
• Systematic literature review of the humanistic and economic burden of focal epilepsy and primary generalized tonic–clonic seizures in adults
  par: Simona Boccaletti, et autres
  Publié: (2024)